Basic information Safety Supplier Related

LY 345899)

Basic information Safety Supplier Related

LY 345899) Basic information

Product Name:
LY 345899)
Synonyms:
  • LY 345899)
  • LY-345899 (LY345899
  • L-Glutamic acid, N-[4-(3-amino-1,2,5,6,6a,7-hexahydro-1,9-dioxoimidazo[1,5-f]pteridin-8(9H)-yl)benzoyl]-
  • (2S)-2-(4-(3-Amino-1,9-dioxo-1,2,5,6,6a,7-hexahydroimidazo[1,5-f]pteridin-8(9H)-yl)benzamido)pentanedioic acid
  • inhibit,LY345899,LY-345899,Inhibitor,LY 345899,Methylenetetrahydrofolate Dehydrogenase (MTHFD)
  • (2S)-2-[(4-{3-amino-1,9-dioxo-1H,4H,5H,6H,6aH,7H,8H,9H-imidazo[1,5-f]pteridin-8-yl}phenyl)formamido]pentanedioic acid
CAS:
10538-99-5
MF:
C20H21N7O7
MW:
471.42
Mol File:
10538-99-5.mol
More
Less

LY 345899) Chemical Properties

Density 
1.82±0.1 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
DMSO:125.0(Max Conc. mg/mL);265.16(Max Conc. mM)
form 
A solid
pka
3.46±0.10(Predicted)
color 
Light yellow to yellow
More
Less

LY 345899) Usage And Synthesis

Biological Activity

LY 345899, a folate analog, is also a methylenetetrahydrofolate dehydrogenase (MTHFD1; DC301) and MTHFD2 inhibitor with IC50 values of 96 nM and 663 nM, respectively, and Ki value for MTHFD1 of 18 nM.

in vitro

LY 345899 could suppress the MTHFD enzyme in the cytoplasm and mitochondria.
LY 345899 could disturb the NADPH and redox homeostases and accelerate cell death under oxidative stress, such as hypoxia, or causing in vitro anchorage independence and in vivo impaired tumor growth and metastasis.

in vivo

LY345899 (Intraperitoneal injection; 5-10 mg/kg; 5 d/wk; 4 weeks) shows potent antitumor activity and displays therapeutic activity against CRC in vivo .

< td class="col1 fwb"> Animal Model: < td class="col1 fwb"> Dosage: table>

target

Ki: 18 nM (MTHFD1); IC50: 96 nM (MTHFD1) and 663 nM (MTHFD2)

LY 345899)Supplier

Shanghai Lollane Biological Technology Co.,Ltd.
Tel
021-52996696,15000506266 15000506266
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Email
2853530910@QQ.com
TargetMol Chemicals Inc.
Tel
+1-781-999-5354 +1-00000000000
Email
marketing@targetmol.com
InvivoChem
Tel
+1-708-310-1919 +1-13798911105
Email
sales@invivochem.cn
Nextpeptide Inc
Tel
+86-0571-81612335 +8613336028439
Email
sales@nextpeptide.com
SW620 or PDX-based BABL/c nude colorectal cancer (CRC) model
5-10 mg/kg
Administration: Intraperitoneal injection; 5-10 mg/kg; 5 d/wk; 4 weeks
Result : Displayed lower cell proliferation indices and higher cell apoptosis. Exhibited no statistically significant weight loss or other signs of acute or delayed toxicity in mice.